Scientific Publications by FDA Staff
Pharm Dev Technol 2013 Nov-Dec;18(6):1265-76
Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms.
Desai D, Wang J, Wen H, Li X, Timmins P
Fixed dose combination (FDC) products are common in the treatment of hypertension, diabetes, human immunodeficiency virus, and tuberculosis. They make it possible to combine two or more drug molecules with different modes of pharmacological actions in a single dosing unit and optimize the treatment. From a patient perspective, they offer convenience, reduced dosing unit burden, and cost savings. From a clinical perspective, aging population in developed countries will need multiple medications to treat age related diseases and co-morbidities. FDC products simplify dosing regimen and enhance patient compliance. As outlined in the article, the number of FDC products has grown over the years and the trend is likely to continue. This review article gives an overview to pharmaceutical scientists about recent trends in the formulation development of the FDC products and provides decision trees to select most optimum formulation development strategy. While some formulation technologies such as multi-layer tablets, multiparticulate systems, active film coating, and hot-melt granulation are discussed in more detail, a few specialized technologies are also introduced briefly to the readers.
|Category: Journal Article, Review|
|PubMed ID: #22339230||DOI: 10.3109/10837450.2012.660699|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-09-22|